Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2011
|
| gptkbp:approvedBy |
gptkb:FDA
metastatic melanoma |
| gptkbp:ATCCode |
L01EC01
|
| gptkbp:brand |
gptkb:Zelboraf
|
| gptkbp:CASNumber |
918504-65-1
|
| gptkbp:chemicalFormula |
C23H18ClF2N3O3S
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:combines |
gptkb:cobimetinib
|
| gptkbp:contraindication |
pregnancy
QT prolongation |
| gptkbp:developedBy |
gptkb:Plexxikon
gptkb:Roche |
| gptkbp:discoveredIn |
2005
|
| gptkbp:eliminationHalfLife |
57 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
PLX4032
|
| gptkbp:indication |
gptkb:BRAF_V600E-positive_melanoma
unresectable melanoma |
| gptkbp:mechanismOfAction |
BRAF inhibitor
|
| gptkbp:metabolism |
gptkb:CYP3A4
|
| gptkbp:sideEffect |
gptkb:cutaneous_squamous_cell_carcinoma
fatigue rash photosensitivity arthralgia |
| gptkbp:synonym |
gptkb:vemurafenib
|
| gptkbp:target |
gptkb:BRAF_V600E_mutation
|
| gptkbp:bfsParent |
gptkb:vemurafenib
|
| gptkbp:bfsLayer |
6
|